BioSpace News Archive

Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announces that management will present at the following investor conferences

AffaMed Therapeutics (“AffaMed”), a global clinical stage biopharmaceutical company dedicated to addressing critical unmet medical needs in ophthalmic, neurological and psychiatric disorders, today announced that China’s National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for a Phase IIb global clinical trial led by AffaMed to evaluate the safety and efficacy of AM006

Zivo Bioscience, Inc. (OTCMKTS:ZIVO) a biotech/agtech R&D company engaged in the development and commercialization of nutritional/nutraceutical product candidates originally derived from proprietary algal cultures, today announced the pricing of its upsized underwritten public offering of 2,760,000 units at a price to the public of $5.00 per unit.

Centessa Pharmaceuticals plc, a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients, announced the pricing of its initial public offering of 16,500,000 American Depositary Shares, each representing one ordinary share at a public offering price of $20.00 per ADS.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021.

As interest and demand for more accurate prostate cancer imaging grows, and with the approval of the first Ga-68 PSMA based prostate imaging agent late last year1, Cardinal Health Nuclear & Precision Health Solutions and Telix Pharmaceuticals Inc. have developed an in-depth white-paper, entitled: “Moving beyond the Myth: Meeting the growing demand for Ga-68 radiopharmaceuticals.”

OPKO Health, Inc. announced that management will be participating in the Jefferies Virtual Healthcare Conference being held June 1-4, 2021.

Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug instruments that provide painless and precise injections, has been invited to present at the “Summer Solstice – Best Ideas from the Buy-Side” conference, which is being held virtually on June 1 st – 4 th , 2021. Arjan Haverhals, Chief Executive Officer and President of Milestone Scientific, is scheduled to present on Wednesday, June 2 nd , 2021 at 2:00 PM

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the Jefferies Virtual Healthcare Conference taking place on June 1 – 4, 2021. Jefferies Virtual Healthcare Conference Date: Friday, June 4 Time: 11:30 am

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received an award of up to $2.6M from the Cystic Fibrosis Foundation.